2005 marked the real beginning of contract manufacturing in Japan,
which had been held back by an overly-cautious regulatory
environment and significant and unique quality and specification
demands in the marketplace.
Japan is getting serious about clinical trial reform after years of
lagging behind the rest of the developed world in the availability
of drugs in the country, which ironically is the world's number two
pharma market behind the...
DiscoveRx and B-Bridge International are to venture into the
Japanese assay market that aims to provide Japanese researchers
with a homogenous GPCR and Kinase assay platform for drug
development and screening.
Companies from Europe, the US and Japan have announced the
construction of new facilities this month, suggesting that despite
a difficult operating environment big pharma is still making
significant capital investments.